Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to UY28498ApriorityCriticalpatent/UY28498A1/en
Publication of UY28498A1publicationCriticalpatent/UY28498A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a una nueva forma cristalina de la sal de adición de ácido metansulfónico de 4- (4-metilpiperazin-1-ilmetil)-N-(4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil) benzamida de la fórmula I, que se puede utilizar, por ejemplo, para terapia de tumores.The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4- (4-methylpiperazin-1-ylmethyl) -N- (4-methyl-3- (4-pyridin-3-yl) pyrimidine- 2-ylamino) phenyl) benzamide of the formula I, which can be used, for example, for tumor therapy.
UY28498A2004-09-022004-09-02
CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINAMINE DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND USE.
UY28498A1
(en)
3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
USE OF 4- (2- (4-METHYLPHENYL SULFANYL) PHENYL) PIPERIDINE AND ACID ADDITION SALTS OF THE SAME FOR THE TREATMENT OF ADHD, MELANCOLIA, DEPRESSION OR RESIDUAL SYMPTOMS OF DEPRESSION; AND SUCH COMPOUND.
DERIVATIVES OF AZAESPIRODECANONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCEDURE TO PREPARE THEM AND USE OF THEM FOR THE TREATMENT OF DIABETES, OBESITY AND CARDIOVASCULAR DISEASES, BETWEEN OTHER